131 related articles for article (PubMed ID: 8676195)
1. Preclinical animal studies with radioiododeoxyuridine.
Kassis AI; Adelstein SJ
J Nucl Med; 1996 Apr; 37(4 Suppl):10S-12S. PubMed ID: 8676195
[TBL] [Abstract][Full Text] [Related]
2. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats.
Kassis AI; Wen PY; Van den Abbeele AD; Baranowska-Kortylewicz J; Makrigiorgos GM; Metz KR; Matalka KZ; Cook CU; Sahu SK; Black PM; Adelstein SJ
J Nucl Med; 1998 Jul; 39(7):1148-54. PubMed ID: 9669385
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.
Kassis AI; Adelstein SJ; Mariani G
Q J Nucl Med; 1996 Sep; 40(3):301-19. PubMed ID: 8961807
[TBL] [Abstract][Full Text] [Related]
4. Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2'- deoxyuridine after intravesical infusion in patients with bladder cancer.
Mariani G; Collecchi P; Baldassarri S; Di Luca L; Buralli S; Fontanini G; Baranowska-Kortylewicz J; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Apr; 37(4 Suppl):16S-19S. PubMed ID: 8676197
[TBL] [Abstract][Full Text] [Related]
5. 5-[125]iodo-2'-deoxyuridine in the radiotherapy of solid CNS tumors in rats.
Kassis AI; Adelstein SJ
Acta Oncol; 1996; 35(7):935-9. PubMed ID: 9004774
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer.
Van den Abbeele AD; Tutrone RF; Berman RM; Baranowska-Kortylewicz J; Barclay PD; Richie JP; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Feb; 37(2):315-20. PubMed ID: 8667069
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled iododeoxyuridine: safety evaluation.
Harrison KA; Dalrymple GV; Baranowska-Kortylewicz J; Holdeman KP; Schneiderman MH; Lieberman RP; Sharp JG; Cohen SM; Leichner PK; Augustine SC; Tempero MA; Taylor RJ; Chiou RK
J Nucl Med; 1996 Apr; 37(4 Suppl):13S-16S. PubMed ID: 8676196
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor.
Kassis AI; Tumeh SS; Wen PY; Baranowska-Kortylewicz J; Van den Abbeele AD; Zimmerman RE; Carvalho PA; Garada BM; DeSisto WC; Bailey NO; Castronovo FP; Mariani G; Black PM; Adelstein SJ
J Nucl Med; 1996 Apr; 37(4 Suppl):19S-22S. PubMed ID: 8676198
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model.
Chi KH; Wang HE; Chen FD; Chao Y; Liu RS; Chou SL; Wang YS; Yen SH
J Nucl Med; 2001 Feb; 42(2):345-51. PubMed ID: 11216535
[TBL] [Abstract][Full Text] [Related]
10. Radioiododeoxyuridine in cancer therapy: an in vitro approach to developing in vivo strategies.
Schneiderman MH; Schneiderman GS
J Nucl Med; 1996 Apr; 37(4 Suppl):6S-9S. PubMed ID: 8676203
[TBL] [Abstract][Full Text] [Related]
11. First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.
Rebischung C; Hoffmann D; Stefani L; Desruet MD; Wang K; Adelstein SJ; Artignan X; Vincent F; Gauchez AS; Zhang H; Fagret D; Vuillez J; Kassis AI; Balosso J
Int J Radiat Biol; 2008 Dec; 84(12):1123-9. PubMed ID: 19061137
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model.
Mairs RJ; Wideman CL; Angerson WJ; Whateley TL; Reza MS; Reeves JR; Robertson LM; Neshasteh-Riz A; Rampling R; Owens J; Allan D; Graham DI
Br J Cancer; 2000 Jan; 82(1):74-80. PubMed ID: 10638969
[TBL] [Abstract][Full Text] [Related]
13. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
14. Potential for tumor therapy with iodine-125 labeled immunoglobulins.
Adelstein SJ; Kassis AI; Baranowska-Kortylewicz J; van den Abbeele AD; Mariani G; Ito S
Int J Rad Appl Instrum B; 1991; 18(1):43-4. PubMed ID: 2010304
[TBL] [Abstract][Full Text] [Related]
15. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver.
Macapinlac HA; Kemeny N; Daghighian F; Finn R; Zhang J; Humm J; Squire O; Larson SM
J Nucl Med; 1996 Apr; 37(4 Suppl):25S-29S. PubMed ID: 8676200
[TBL] [Abstract][Full Text] [Related]
16. 5-[123I/125I]iodo-2'-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting.
Semnani ES; Wang K; Adelstein SJ; Kassis AI
J Nucl Med; 2005 May; 46(5):800-6. PubMed ID: 15872354
[TBL] [Abstract][Full Text] [Related]
17. Differential cytotoxicity of [123I]IUdR, [125I]IUdR and [131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire.
Neshasteh-Riz A; Mairs RJ; Angerson WJ; Stanton PD; Reeves JR; Rampling R; Owens J; Wheldon TE
Br J Cancer; 1998; 77(3):385-90. PubMed ID: 9472632
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer.
Mariani G; Di Sacco S; Volterrani D; Di Luca L; Buralli S; Di Stefano R; Baranowska-Kortylewicz J; Bonora D; Matteucci F; Ricci S; Bellina CR; Falcone A; Salvadori PA; Mosca F; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Apr; 37(4 Suppl):22S-25S. PubMed ID: 8676199
[TBL] [Abstract][Full Text] [Related]
19. 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.
Vaidyanathan G; Larsen RH; Zalutsky MR
Cancer Res; 1996 Mar; 56(6):1204-9. PubMed ID: 8640798
[TBL] [Abstract][Full Text] [Related]
20. 5-123I/125I-iodo-2'-deoxyuridine for cancer diagnosis and therapy.
Kassis AI
J Nucl Med Allied Sci; 1990; 34(4):299-303. PubMed ID: 2090794
[No Abstract] [Full Text] [Related]
[Next] [New Search]
